Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Inclusion Criteria

• •1. Urinary albumin excretion of ≤3000 μg of creatinine
• •2. Stage 3 CKD
• •3. Plasma iPTH: \> 70 pg/mL and \< 500 pg/mL
• •4. Serum Ca: ≥ 8.4 mg/dL and \< 10.0 mg/dL
• •5. Serum P: ≥ 2.0 mg/dL and \< 5.0 mg/dL
• •6. Serum 25-hydroxyvitamin D: \> 10 ng/mL and \< 29 ng/mL.
• •7. Discontinue vitamin D use for duration of study